Dongcheng Pharmaceutical Gets NMPA Green Light for PSMA PET Imaging Drug
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced it has received approval from...
Cancer
CSPC Pharmaceutical’s Albumin-Bound Docetaxel Receives Orphan Drug Designation for Gastric Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received an orphan drug...
Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors
Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...
Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...
CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment
China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG:...
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma
China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for...
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...
Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005...
Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...
Lepu Biopharma’s Pucotenlimab Receives Conditional NMPA Approval for MSI-H/dMMR Tumors
The National Medical Products Administration (NMPA) has granted conditional market approval to Lepu Biopharma Co.,...
Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in...
InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone
China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade...
Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...
InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018
China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt...
DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its...
Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx
Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant...
Eli Lilly’s Retevmo Wins Special Approval in China’s Lecheng Medical Pilot Zone
Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor...